Navigation Links
MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology
Date:5/21/2009

Scientists have determined how to produce replication-competent viruses with key toxicities removed, providing a new platform for development of improved cancer treatments and better vaccines for a broad range of viral diseases.

Cellular microRNA molecules regulate the stability of mRNA in different cell types, and this newly-understood mechanism provides the possibility to engineer viruses for cell-specific inactivation. Cancer Research UK scientists at the University of Oxford, United Kingdom, with support from colleagues at Vrije Universiteit, Amsterdam, report that this approach can be used to regulate proliferation of adenovirus in a study published May 22 in the open-access journal PLoS Pathogens.

Adenovirus is a DNA virus widely used in cancer therapy but which causes hepatic disease in mice. Professor Len Seymour and colleagues found that introducing sites into the virus genome that are recognized by microRNA 122 leads to hepatic degradation of important viral mRNA, thereby diminishing the virus' ability to adversely affect the liver, while maintaining its ability to replicate in and kill tumor cells.

Tumor-killing replicating viruses are a hot topic in the biotherapeutics arena, with many clinical trials ongoing worldwide. That Professor Seymour's group set out to and has now defined a mechanism whereby wild type virus potency could be maintained in tumor cells but the virus could be 'turned off' in tissues vulnerable to pathology adds important information to the current base of knowledge.

"This approach is surprisingly effective and quite versatile. It could find a range of applications in controlling the activity of therapeutic viruses, both for cancer research and also to engineer a new generation of conditionally-replicating vaccines, where the vaccine pathogen is disabled in its primary sites of toxicity," Professor Seymour says.

The present study was intended mainly to explore and demonstrate the potential of this new mechanism to regulate virus activity. Although the current tumor-killing virus is useful in mice, transfer of the technology into the clinical setting will require re-engineering of the virus to overcome virus pathologies seen in humans, and it will be at least two years before this can be tested in the clinics.


'/>"/>

Contact: Emma Gilgunn-Jones
emma.gilgunn-jones@cancer.org.uk
44-207-061-8311
Public Library of Science
Source:Eurekalert

Related medicine news :

1. Exiqon Announces New Grant Program for MicroRNA Research
2. Throwing the micro switch: MicroRNA may link smoking risk gene to neurobiology of addiction
3. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
4. MicroRNA undermines tumor suppression
5. MicroRNAs make for safer cancer treatments
6. Gladstone scientists identify single microRNA that controls blood vessel development
7. Putting microRNAs on the stem cell map
8. Need microRNA processing? Get Smad
9. MicroRNA controls expression of oncogenes
10. MicroRNAs appear essential for retinal health
11. MicroRNAs, EMT and cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... CT (PRWEB) , ... December 07, 2016 , ... A ... prompted an outpouring of comments on social media that offer a rare glimpse into ... psychiatrist, leading ADHD authority and New York Times bestselling author, has described people with ...
(Date:12/7/2016)... MA (PRWEB) , ... December 07, 2016 , ... They ... They are sisters and wives, brothers and fathers, from New England and around the ... and its stigma, and are brought together in a beautiful and compelling new photographic ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... performance connectors, is now promoting to the US market its advanced highly customizable ... LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for a wide ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco ... services to residents in the Sacramento/Folsom region, is initiating a charity event to ... The Another Choice Another Chance treatment center in Sacramento works to provide area ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   Arena Pharmaceuticals, Inc. ... it has completed enrollment in the ralinepag phase 2 ... targeting the prostacyclin pathway for the treatment of pulmonary ... at sites globally. "This marks an important ... of our strategic focus on our pipeline," said ...
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion Group, ... Professional, BioRx, MedPro Rx, and XAS Infusion Suites. To ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... we continue to build on the work we have done, we ...
(Date:12/7/2016)... 2016   Rx Savings Solutions has partnered with ... its Public Employees Insurance Agency (PEIA) to offer more than ... healthcare software, ultimately saving money on their prescriptions. ... members with access to our software that will alert them ... therapy can be found," says Michael Rea , founder ...
Breaking Medicine Technology: